Wells Fargo lowered the firm’s price target on Editas Medicine (EDIT) to $9 from $27 and keeps an Equal Weight rating on the shares. With in vivo editing of HSPCs achieved preclinically, the firm thinks Editas’ decision to pivot to in vivo SCD approach while partnering out reni-cel could represent a more effective use of its expertise and resources to create value.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EDIT:
- Editas Medicine price target lowered to $12 from $20 at Chardan
- Editas Medicine price target lowered to $10 from $18 at Baird
- Editas Medicine announces progress towards 2024 goals
- Editas Medicine, Genevant Sciences enter collaboration and license agreement
- MaxCyte appoints Cynthia Collins to board of directors